Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Phase I & II Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Phase I & II Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
A Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplant in Patients With Fanconi Anemia.
CD45 (YTH-24 and YTH 54) and CD52 (CamPath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia.
Status: Archived
Baylor School of Medicine
mi
from
Houston, TX
A Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplant in Patients With Fanconi Anemia.
CD45 (YTH-24 and YTH 54) and CD52 (CamPath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia.
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
mi
from
Houston, TX
A Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplant in Patients With Fanconi Anemia.
CD45 (YTH-24 and YTH 54) and CD52 (CamPath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia.
Status: Archived
Texas Children's Hospital - Feigin Center
mi
from
Houston, TX
A Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplant in Patients With Fanconi Anemia.
CD45 (YTH-24 and YTH 54) and CD52 (CamPath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia.
Status: Archived
Updated: 1/1/1970
Texas Children's Hospital - Feigin Center
mi
from
Houston, TX
A Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplant in Patients With Fanconi Anemia.
CD45 (YTH-24 and YTH 54) and CD52 (CamPath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia.
Status: Archived
Houston Methodist Hospital
mi
from
Houston, TX
A Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplant in Patients With Fanconi Anemia.
CD45 (YTH-24 and YTH 54) and CD52 (CamPath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia.
Status: Archived
Updated: 1/1/1970
Houston Methodist Hospital
mi
from
Houston, TX
Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot
Status: Archived
Washington Hospital Center
mi
from
Washington,
Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot
Status: Archived
Updated: 1/1/1970
Washington Hospital Center
mi
from
Washington,
Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot
Status: Archived
Washington VA Medical Center
mi
from
Washington,
Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot
Status: Archived
Updated: 1/1/1970
Washington VA Medical Center
mi
from
Washington,
Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot
Status: Archived
Durham VA Medical Center
mi
from
Durham, NC
Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot
Status: Archived
Updated: 1/1/1970
Durham VA Medical Center
mi
from
Durham, NC
Codeine in Sickle Cell Disease
The Effects of Cytochrome P450 2D6 Genotype on Pain Management With Codeine in Sickle Cell Disease
Status: Archived
University of Illinois College of Medicine
mi
from
Chicago, IL
Codeine in Sickle Cell Disease
The Effects of Cytochrome P450 2D6 Genotype on Pain Management With Codeine in Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
University of Illinois College of Medicine
mi
from
Chicago, IL
Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia
A Pilot Trial of Oxandrolone for the Treatment of Bone Marrow Aplasia in Patients With Fanconi Anemia
Status: Archived
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia
A Pilot Trial of Oxandrolone for the Treatment of Bone Marrow Aplasia in Patients With Fanconi Anemia
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
Efficacy of Treating Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF) on Ventricular Function, Exercise Capacity and Health Status
Status: Archived
Clinical Cardiovascular Research Laboratory for the Elderly
mi
from
New York, NY
Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
Efficacy of Treating Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF) on Ventricular Function, Exercise Capacity and Health Status
Status: Archived
Updated: 1/1/1970
Clinical Cardiovascular Research Laboratory for the Elderly
mi
from
New York, NY
Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer
Placebo-Controlled Pilot Study to Assess the Post-Operative Administration of Epoetin Alfa on Patients Undergoing Abdominal or Pelvic Surgery for Malignancy
Status: Archived
University of Florida Gainesville
mi
from
Gainesville, FL
Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer
Placebo-Controlled Pilot Study to Assess the Post-Operative Administration of Epoetin Alfa on Patients Undergoing Abdominal or Pelvic Surgery for Malignancy
Status: Archived
Updated: 1/1/1970
University of Florida Gainesville
mi
from
Gainesville, FL
Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study
Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study
Status: Archived
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study
Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status: Archived
University of South Alabama Medical Center
mi
from
Mobile, AL
Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status: Archived
Updated: 1/1/1970
University of South Alabama Medical Center
mi
from
Mobile, AL
Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status: Archived
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status: Archived
Updated: 1/1/1970
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status: Archived
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status: Archived
Updated: 1/1/1970
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status: Archived
Rush University Medical Center
mi
from
Chicago, IL
Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
mi
from
Chicago, IL
Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status: Archived
Associates in Women's Health
mi
from
Wichita, KA
Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status: Archived
Updated: 1/1/1970
Associates in Women's Health
mi
from
Wichita, KA
Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status: Archived
Schwartz Gynecologic Oncology, PLLC
mi
from
Brightwaters, NY
Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status: Archived
Updated: 1/1/1970
Schwartz Gynecologic Oncology, PLLC
mi
from
Brightwaters, NY
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and GCSF in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and GCSF in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Skin and Blood Research Samples From Healthy Volunteers and Sickle Cell Anemia Patients
Acquisition of Skin Biopsies and Blood Samples From Normal Volunteers and Sickle Cell Anemia Patients for Research Purposes
Status: Archived
Washington University
mi
from
St. Louis, MO
Skin and Blood Research Samples From Healthy Volunteers and Sickle Cell Anemia Patients
Acquisition of Skin Biopsies and Blood Samples From Normal Volunteers and Sickle Cell Anemia Patients for Research Purposes
Status: Archived
Updated: 1/1/1970
Washington University
mi
from
St. Louis, MO
A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension
A Pilot Study of the Effects of Chronic Red Blood Cell Transfusion in Sickle Cell Disease On Pulmonary Hypertension in Patients With Sickle Cell Disease
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension
A Pilot Study of the Effects of Chronic Red Blood Cell Transfusion in Sickle Cell Disease On Pulmonary Hypertension in Patients With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease
A Study to Evaluate the Effect of the Treatment of Anemia on Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease
Status: Archived
Baltimore VA Medical Center
mi
from
Baltimore, MD
Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease
A Study to Evaluate the Effect of the Treatment of Anemia on Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease
Status: Archived
Updated: 1/1/1970
Baltimore VA Medical Center
mi
from
Baltimore, MD
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Children's Hospital Denver
mi
from
Aurora, CO
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
Children's Hospital Denver
mi
from
Aurora, CO
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Howard University Hospital
mi
from
Washington,
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
Howard University Hospital
mi
from
Washington,
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
University of Miami School of Medicine
mi
from
Miami, FL
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
University of Miami School of Medicine
mi
from
Miami, FL
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Georgia Health Sciences University
mi
from
Augusta, GA
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
Georgia Health Sciences University
mi
from
Augusta, GA
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
University of Illinois College of Medicine
mi
from
Chicago, IL
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
University of Illinois College of Medicine
mi
from
Chicago, IL
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
LSU Health Science Center Shreveport
mi
from
Shreveport, LA
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
LSU Health Science Center Shreveport
mi
from
Shreveport, LA
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Albert Einstein College of Medicine
mi
from
Bronx, NY
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
Albert Einstein College of Medicine
mi
from
Bronx, NY
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Baylor University Medical Center - Dallas
mi
from
Dallas, TX
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
Baylor University Medical Center - Dallas
mi
from
Dallas, TX
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation for Children With Non-Malignant Diseases Who Have Been Multiply Transfused: a Pilot Study
Status: Archived
Children's Doctor
mi
from
Houston, TX
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation for Children With Non-Malignant Diseases Who Have Been Multiply Transfused: a Pilot Study
Status: Archived
Updated: 1/1/1970
Children's Doctor
mi
from
Houston, TX
Hypophosphatemia With Intravenous Ferric Carboxymaltose Versus Iron Dextran in Women With Iron Deficiency Secondary to Heavy Uterine Bleeding
A Randomized, Controlled Study to Investigate the Safety and Explore the Mechanism of Hypophosphatemia With Intravenous Ferric Carboxymaltose (FCM) Versus Iron Dextran in Women With Iron Deficiency Secondary to Heavy Uterine Bleeding
Status: Archived
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Hypophosphatemia With Intravenous Ferric Carboxymaltose Versus Iron Dextran in Women With Iron Deficiency Secondary to Heavy Uterine Bleeding
A Randomized, Controlled Study to Investigate the Safety and Explore the Mechanism of Hypophosphatemia With Intravenous Ferric Carboxymaltose (FCM) Versus Iron Dextran in Women With Iron Deficiency Secondary to Heavy Uterine Bleeding
Status: Archived
Updated: 1/1/1970
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
The Bleeding and Clotting Disorders Institute
mi
from
Peoria, IL
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
The Bleeding and Clotting Disorders Institute
mi
from
Peoria, IL
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
St. Vincent Indianapolis Hospital
mi
from
Indianapolis, IN
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
St. Vincent Indianapolis Hospital
mi
from
Indianapolis, IN
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
New England Hemophilia Center
mi
from
Worcester, MA
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
New England Hemophilia Center
mi
from
Worcester, MA
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Vanderbilt Hemostatis and Thrombosis Clinic
mi
from
Nashville, TN
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
Vanderbilt Hemostatis and Thrombosis Clinic
mi
from
Nashville, TN
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Puget Sound Blood Center
mi
from
Seattle, WA
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
Puget Sound Blood Center
mi
from
Seattle, WA
Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia
Etanercept (Enbrel) in Children With Fanconi Anemia and Early Bone Marrow Failure: A Pilot Study
Status: Archived
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia
Etanercept (Enbrel) in Children With Fanconi Anemia and Early Bone Marrow Failure: A Pilot Study
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
UCLA Orthodpedic Hospital
mi
from
Los Angeles, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
UCLA Orthodpedic Hospital
mi
from
Los Angeles, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Uc Irvine Medical Center
mi
from
Orange, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
Uc Irvine Medical Center
mi
from
Orange, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
University of Colorado, Boulder
mi
from
Boulder, CO
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
mi
from
Boulder, CO
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Georgetown Univ Med Ctr
mi
from
Washington,
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
mi
from
Washington,
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Rush University Medical Center
mi
from
Chicago, IL
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
mi
from
Chicago, IL